BCL2L1 and prostate cancer: Epigallocatechin-3-gallate (EGCG) and ibuprofen synergistically induced apoptosis in prostate cancer cells via regulating alternative splicing of MCL-1 and BCL-X, specifically by down-regulating the mRNA levels of anti-apoptotic isoforms (MCL-1L and BCL-XL) with a concomitant increase in the transcript levels of pro-apoptotic MCL-1S and BCL-XS, respectively [32].